However, no significant difference seen in efficacy or safety outcomes for clopidogrel versus no antiplatelet therapy<\/em><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n FRIDAY, Sept. 16, 2022 (HealthDay News) — Full-dose anticoagulation reduces thrombotic complications in critically ill patients with COVID-19, according to a study published online Aug. 29 in Circulation <\/em>to coincide with the European Society of Cardiology Congress 2022, held from Aug. 26 to 29 in Barcelona, Spain.<\/p>\n Erin A. Bohula, M.D., D.Phil., from Brigham and Women’s Hospital in Boston, and colleagues examined the safety and efficacy of prophylactic full-dose anticoagulation and antiplatelet therapy in critically ill COVID-19 patients. A total of 390 patients at 34 centers were randomly assigned between anticoagulation strategies (full-dose anticoagulation or standard-dose prophylactic anticoagulation) and 292 were randomly assigned between antiplatelet strategies (clopidogrel or no antiplatelet therapy).<\/p>\n The researchers found that the proportion of wins was greater for full-dose versus standard-dose anticoagulant (12.3 versus 6.4 percent; win ratio, 1.95). The results were consistent in a time-to-event analysis for the primary efficacy end point (hierarchical composite of death due to venous or arterial thrombosis, pulmonary embolism, clinically evident deep venous thrombosis [DVT], type 1 myocardial infarction, ischemic stroke, systemic embolic event or acute limb ischemia, or clinically silent DVT, through hospital discharge or 28 days; 9.9 versus 15.2 percent; hazard ratio, 0.56). The primary safety end point of fatal or life-threatening bleeding occurred in 2.1 and 0.5 percent on full-dose and standard-dose anticoagulation, respectively. No differences were seen in the primary efficacy or safety end points for clopidogrel versus no antiplatelet therapy.<\/p>\n “COVID-PACT shows that, compared with standard-dose prophylaxis, full-dose anticoagulation more effectively prevents the clotting complications of COVID-19,” a coauthor said in a statement.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n More Information<\/a><\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/i><\/p>\n